Page 2272 - Williams Hematology ( PDFDrive )

2246 Part XII: Hemostasis and Thrombosis Chapter 131: The Antiphospholipid Syndrome 2247

73. Krikun G, Lockwood CJ, Wu XX, et al: The expression of the placental anticoagulant 104. Ames PR, Tommasino C, Iannaccone L, et al: Coagulation activation and fibrinolytic
protein, annexin V, by villous trophoblasts: Immunolocalization and in vitro regulation. imbalance in subjects with idiopathic antiphospholipid antibodies—A crucial role for
Placenta 15:601–612, 1994. acquired free protein S deficiency. Thromb Haemost 76:190–194, 1996.
74. Ueki H, Mizushina T, Laoharatchatathanin T, et al: Loss of maternal annexin A5 increases 105. Schousboe I, Rasmussen MS: Synchronized inhibition of the phospholipid medi-
the likelihood of placental platelet thrombosis and foetal loss. Sci Rep 2:827, 2012. ated autoactivation of factor XII in plasma by beta 2-glycoprotein I and anti-beta 2-
75. Wang X, Campos B, Kaetzel MA, Dedman JR: Annexin V is critical in the maintenance glycoprotein I. Thromb Haemost 73:798–804, 1995.
of murine placental integrity. Am J Obstet Gynecol 180:1008–1016, 1999. 106. Sacre SM, Stannard AK, Owen JS: Apolipoprotein E (apoE) isoforms differentially
76. Rand JH, Wu XX, Andree HA, et al: Pregnancy loss in the antiphospholipid-antibody induce nitric oxide production in endothelial cells. FEBS Lett 540:181–187, 2003.
syndrome—A possible thrombogenic mechanism. N Engl J Med 337:154–160, 1997. 107. Yang XV, Banerjee Y, Fernandez JA, et al: Activated protein C ligation of ApoER2
77. van Heerde WL, Poort S, van ‘t Veer C, et al: Binding of recombinant annexin V to (LRP8) causes Dab1-dependent signaling in U937 cells. Proc Natl Acad Sci U S A 106:
endothelial cells: Effect of annexin V binding on endothelial-cell-mediated thrombin 274–279, 2009.
formation. Biochem J 302:305–312, 1994. 108. Shi T, Giannakopoulos B, Yan X, et al: Anti-beta2-glycoprotein I antibodies in complex
78. Rand JH, Wu XX, Andree HAM, et al: Antiphospholipid antibodies accelerate plasma with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycopro-
coagulation by inhibiting annexin-V binding to phospholipids: A “lupus procoagulant” tein Ib-IX-V. Arthritis Rheum 54:2558–2567, 2006.
phenomenon. Blood 92:1652–1660, 1998. 109. Lutters BC, Derksen RH, Tekelenburg WL, et al: Dimers of beta 2-glycoprotein I
79. Rand JH, Wu XX, Quinn AS, et al: Human monoclonal antiphospholipid antibodies increase platelet deposition to collagen via interaction with phospholipids and the apo-
disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: Evidence lipoprotein E receptor 2′. J Biol Chem 278:33831–33838, 2003.
from atomic force microscopy and functional assay. Am J Pathol 163:1193–1200, 2003. 110. Graham A, Ford I, Morrison R, et al: Anti-endothelial antibodies interfere in apoptotic
80. Rand JH, Wu XX, Lapinski R, et al: Detection of antibody-mediated reduction of cell clearance and promote thrombosis in patients with antiphospholipid syndrome. J
annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid Immunol 182:1756–1762, 2009.
syndrome. Blood 104:2783–2790, 2004. 111. Sammaritano LR: Significance of aPL IgG subclasses. Lupus 5:436–439, 1996.
81. Wu XX, Pierangeli SS, Rand JH: Resistance to annexin A5 binding and anticoagulant 112. Salmon JE, Girardi G, Holers VM: Complement activation as a mediator of antiphos-
activity in plasmas from patients with the antiphospholipid syndrome but not with pholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 61(Suppl 2):
syphilis. J Thromb Haemost 4:271–273, 2006. ii46–ii50, 2002.
82. Hanly JG, Smith SA: Anti-beta2-glycoprotein I (GPI) autoantibodies, annexin V bind- 113. Salmon JE, Girardi G: The role of complement in the antiphospholipid syndrome. Curr
ing and the anti-phospholipid syndrome. Clin Exp Immunol 120:537–543, 2000. Dir Autoimmun 7:133–148, 2004.
83. Tomer A: Antiphospholipid antibody syndrome: Rapid, sensitive, and specific flow 114. Girardi G, Redecha P, Salmon JE: Heparin prevents antiphospholipid antibody-induced
cytometric assay for determination of anti-platelet phospholipid autoantibodies. J Lab fetal loss by inhibiting complement activation. Nat Med 10:1222–1226, 2004.
Clin Med 139:147–154, 2002. 115. Redecha P, Tilley R, Tencati M, et al: Tissue factor: A link between C5a and neutrophil
84. Tomer A, Bar-Lev S, Fleisher S, et al: Antiphospholipid antibody syndrome: The flow activation in antiphospholipid antibody induced fetal injury. Blood 110:2423–2431,
cytometric annexin A5 competition assay as a diagnostic tool. Br J Haematol 139:113– 2007.
120, 2007. 116. Redecha P, Franzke CW, Ruf W, et al: Neutrophil activation by the tissue factor/Factor
85. Gaspersic N, Ambrozic A, Bozic B, et al: Annexin A5 binding to giant phospholipid VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome.
vesicles is differentially affected by anti-beta2-glycoprotein I and anti-annexin A5 anti- J Clin Invest 118:3453–3461, 2008.
bodies. Rheumatology 46:81–86, 2007. 117. Zhou H, Wolberg AS, Roubey RA: Characterization of monocyte tissue factor activity
86. Rand JH, Wu XX, Guller S, et al: Reduction of annexin-V (placental anticoagulant induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 104:2353–
protein-I) on placental villi of women with antiphospholipid antibodies and recurrent 2358, 2004.
spontaneous abortion. Am J Obstet Gynecol 171:1566–1572, 1994. 118. Roubey RA: New approaches to prevention of thrombosis in the antiphospholipid
87. Cederholm A, Svenungsson E, Jensen-Urstad K, et al: Decreased binding of annexin syndrome: Hopes, trials, and tribulations. Arthritis Rheum 48:3004–3008, 2003.
V to endothelial cells: A potential mechanism in atherothrombosis of patients with 119. Martini F, Farsi A, Gori AM, et al: Antiphospholipid antibodies (aPL) increase the
systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 25:198–203, 2005. potential monocyte procoagulant activity in patients with systemic lupus erythematosus.
88. Dueymes M, Levy Y, Ziporen L, et al: Do some antiphospholipid antibodies target Lupus 5:206–211, 1996.
endothelial cells? Ann Med Interne (Paris) 147(Suppl 1):22–23, 1996. 120. Bu C, Gao L, Xie W, et al: Beta2-glycoprotein i is a cofactor for tissue plasminogen
89. Del-Papa N, Raschi E, Catelli L, et al: Endothelial cells as a target for antiphospho- activator-mediated plasminogen activation. Arthritis Rheum 60:559–568, 2009.
lipid antibodies: Role of anti-beta 2 glycoprotein I antibodies. Am J Reprod Immunol 121. Riewald M, Ruf W: Protease-activated receptor-1 signaling by activated protein C in
38:212–217, 1997. cytokine-perturbed endothelial cells is distinct from thrombin signaling. J Biol Chem
90. Matsuda J, Gotoh M, Gohchi K, et al: Anti-endothelial cell antibodies to the endothelial 280:19808–19814, 2005.
hybridoma cell line (EAhy926) in systemic lupus erythematosus patients with antiphos- 122. Niessen F, Furlan-Freguia C, Fernandez JA, et al: Endogenous EPCR/aPC-PAR1
pholipid antibodies. Br J Haematol 97:227–232, 1997. signaling prevents inflammation-induced vascular leakage and lethality. Blood 113:
91. Navarro M, Cervera R, Teixido M, et al: Antibodies to endothelial cells and to beta 2859–2866, 2009.
2-glycoprotein I in the antiphospholipid syndrome: Prevalence and isotype distribu- 123. Nojima J, Kuratsune H, Suehisa E, et al: Acquired activated protein C resistance associ-
tion. Br J Rheumatol 35:523–528, 1996. ated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk
92. Simantov R, Lo SK, Gharavi A, et al: Antiphospholipid antibodies activate vascular factor for venous thromboembolism. Clin Chem 51:545–552, 2005.
endothelial cells. Lupus 5:440–441, 1996. 124. de Laat B, Eckmann CM, van SM, et al: Correlation between the potency of a beta2-
93. Meroni PL, Papa ND, Beltrami B, et al: Modulation of endothelial cell function by anti- glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated
phospholipid antibodies. Lupus 5:448–450, 1996. protein C. Blood Coagul Fibrinolysis 19:757–764, 2008.
94. Cockrell E, Espinola RG, McCrae KR: Annexin A2: Biology and relevance to the anti- 125. Hurtado V, Montes R, Gris JC, et al: Autoantibodies against EPCR are found in anti-
phospholipid syndrome. Lupus 17:943–951, 2008. phospholipid syndrome and are a risk factor for fetal death. Blood 104:1369–1374,
95. Romay-Penabad Z, Montiel-Manzano MG, Shilagard T, et al: Annexin A2 is involved 2004.
in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood 126. Proulle V, Furie RA, Merrill-Skoloff G, Furie BC: Platelets are required for enhanced
114:3074–3083, 2009. activation of the endothelium and fibrinogen in a mouse thrombosis model of APS.
96. Raschi E, Borghi MO, Grossi C, et al: Toll-like receptors: Another player in the patho- Blood 124:611–622, 2014.
genesis of the anti-phospholipid syndrome. Lupus 17:937–942, 2008. 127. Lin YL, Wang CT: Activation of human platelets by the rabbit anticardiolipin antibodies.
97. Xie H, Sheng L, Zhou H, Yan J: The role of TLR4 in pathophysiology of antiphos- Blood 80:3135–3143, 1992.
pholipid syndrome-associated thrombosis and pregnancy morbidity. Br J Haematol 128. van Lummel M, Pennings MT, Derksen RH, et al: The binding site in (beta)2-glycopro-
164:165–176, 2014. tein I for ApoER2′ on platelets is located in domain V. J Biol Chem 280:36729–36736,
98. Brandt KJ, Fickentscher C, Boehlen F, et al: NF-kappaB is activated from endosomal 2005.
compartments in antiphospholipid antibodies-treated human monocytes. J Thromb 129. Forastiero RR, Martinuzzo ME, Broze GJ: High titers of autoantibodies to tissue fac-
Haemost 12:779–791, 2014. tor pathway inhibitor are associated with the antiphospholipid syndrome. J Thromb
99. Raschi E, Testoni C, Bosisio D, et al: Role of the MyD88 transduction signaling pathway Haemost 1:718–724, 2003.
in endothelial activation by antiphospholipid antibodies. Blood 101:3495–3500, 2003. 130. Witztum JL, Horkko S: The role of oxidized LDL in atherogenesis: Immunological
100. Vega-Ostertag ME, Ferrara DE, Romay-Penabad Z, et al: Role of p38 mitogen-activated response and anti-phospholipid antibodies. Ann N Y Acad Sci 811:88–96, 1997.
protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell 131. Vaarala O: Antiphospholipid antibodies and atherosclerosis. Lupus 5:442–447, 1996.
activation. J Thromb Haemost 5:1828–1834, 2007. 132. Lopez LR, Kobayashi K, Matsunami Y, Matsuura E: Immunogenic oxidized low-density
101. Cesarman-Maus G, Rios-Luna NP, Deora AB, et al: Autoantibodies against the fibrino- lipoprotein/beta2-glycoprotein i complexes in the diagnostic management of athero-
lytic receptor, annexin 2, in antiphospholipid syndrome. Blood 107:4375–4382, 2006. sclerosis. Clin Rev Allergy Immunol 37:12–19, 2009.
102. Chen PP, Yang CD, Ede K, et al: Some antiphospholipid antibodies bind to hemostasis 133. Canaud G, Bienaime F, Tabarin F, et al: Inhibition of the mTORC pathway in the anti-
and fibrinolysis proteases and promote thrombosis. Lupus 17:916–921, 2008. phospholipid syndrome. N Engl J Med 371:303–312, 2014.
103. Cugno M, Cabibbe M, Galli M, et al: Antibodies to tissue-type plasminogen activator 134. Krnic BS, O’Connor CR, Looney SW, et al: A retrospective review of 61 patients with
(tPA) in patients with antiphospholipid syndrome: Evidence of interaction between the antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch
antibodies and the catalytic domain of tPA in 2 patients. Blood 103:2121–2126, 2004. Intern Med 157:2101–2108, 1997.

Kaushansky_chapter 131_p2233-2252.indd 2247 9/18/15 5:10 PM